Literature DB >> 32086571

Super early detailed assessment of lower urinary tract symptoms after holmium laser enucleation of the prostate (HoLEP): a prospective study.

Sascha A Ahyai1, Irina Marik2, Tim A Ludwig2, Andreas Becker3, Saman Asdjodi4, Luis Kluth3, Felix Chun3, Margit Fisch2, Marianne Schmid4.   

Abstract

PURPOSE: To prospectively investigate early and consecutive changes of lower urinary tract symptoms (LUTS), specifically storage symptoms after holmium laser enucleation of the prostate (HoLEP).
METHODS: Patients referred for HoLEP completed the International Prostatic Symptom Score (IPSS) the day before, at discharge, and 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, and 52 weeks after HoLEP. Total IPSS was stratified into mild (score 0-7), moderate (8-19), and severe (20-35) LUTS. Storage symptoms were sub-stratified into storage "negative" and "positive". IPSS changes served as the main postoperative outcome. Mixed linear models identified risk factors affecting postoperative recovery of LUTS.
RESULTS: Between December 2010 and 2012, 144 consecutive HoLEP patients were prospectively included in the study. Preoperatively 57.6% of the cohort reported severe storage symptoms (mean total IPSS: 22.6 ± 5.0). Total IPSS decreased significantly immediately after surgery (p < 0.001). Patients with severe LUTS, storage-positive sub-score, and high maximum urinary flow rate were affected by a rebound of mainly storage symptoms 6-8 weeks after HoLEP and prolonged recovery from LUTS. Of these, about 7.4% presented persisting urge complaints. Finally, 12 weeks following HoLEP, the vast majority of patients were symptom-free. Limitations of this study include missing urodynamic workup and a comparative patient cohort.
CONCLUSION: Immediately after HoLEP, patients experience a significant decrease of LUTS. Continuous symptom recovery seems to be hampered in patients with severe and storage-positive baseline symptoms. (De-novo) storage symptoms slightly affect postoperative recovery. Quality of life is restored to a stable and significantly improved status 3 months after surgery.

Entities:  

Keywords:  Benign prostate enlargement; Holmium laser enucleation of the prostate; Lower urinary tract symptoms; Quality of life; Storage symptoms

Mesh:

Year:  2020        PMID: 32086571     DOI: 10.1007/s00345-020-03126-x

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  20 in total

1.  Holmium laser enucleation versus transurethral resection of the prostate: 3-year follow-up results of a randomized clinical trial.

Authors:  Sascha A Ahyai; Karin Lehrich; Rainer M Kuntz
Journal:  Eur Urol       Date:  2007-04-25       Impact factor: 20.096

2.  Assessing the Learning Curve of Holmium Laser Enucleation of Prostate (HoLEP). A Systematic Review.

Authors:  Spyridon Kampantais; Panagiotis Dimopoulos; Ali Tasleem; Peter Acher; Karen Gordon; Anthony Young
Journal:  Urology       Date:  2018-07-04       Impact factor: 2.649

3.  Holmium laser enucleation of the prostate: long-term durability of clinical outcomes and complication rates during 10 years of followup.

Authors:  Hazem M Elmansy; Ahmed Kotb; Mostafa M Elhilali
Journal:  J Urol       Date:  2011-09-23       Impact factor: 7.450

4.  Diagnostic value of International Prostate Symptom Score voiding-to-storage subscore ratio in male lower urinary tract symptoms.

Authors:  C-H Liao; S-D Chung; H-C Kuo
Journal:  Int J Clin Pract       Date:  2011-05       Impact factor: 2.503

Review 5.  Holmium laser enucleation of the prostate (HoLEP): a review and update.

Authors:  Akhil K Das; Seth Teplitsky; Mitchell R Humphreys
Journal:  Can J Urol       Date:  2019-08       Impact factor: 1.344

Review 6.  Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement.

Authors:  Sascha A Ahyai; Peter Gilling; Steven A Kaplan; Rainer M Kuntz; Stephan Madersbacher; Francesco Montorsi; Mark J Speakman; Christian G Stief
Journal:  Eur Urol       Date:  2010-06-11       Impact factor: 20.096

Review 7.  EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.

Authors:  Christian Gratzke; Alexander Bachmann; Aurelien Descazeaud; Marcus J Drake; Stephan Madersbacher; Charalampos Mamoulakis; Matthias Oelke; Kari A O Tikkinen; Stavros Gravas
Journal:  Eur Urol       Date:  2015-01-19       Impact factor: 20.096

8.  Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: a randomized prospective trial in 200 patients.

Authors:  Rainer M Kuntz; Sascha Ahyai; Karin Lehrich; Amr Fayad
Journal:  J Urol       Date:  2004-09       Impact factor: 7.450

9.  Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center prospective randomized trial in patients with obstructive benign prostatic hyperplasia.

Authors:  Francesco Montorsi; Richard Naspro; Andrea Salonia; Nazareno Suardi; Alberto Briganti; Matteo Zanoni; Sergio Valenti; Ivano Vavassori; Patrizio Rigatti
Journal:  J Urol       Date:  2008-05       Impact factor: 7.450

10.  Holmium Laser Enucleation of the Prostate: Modified Two-Lobe Technique versus Traditional Three-Lobe Technique-A Randomized Study.

Authors:  Congcong Xu; Zhen Xu; Caixiu Lin; Sheng Feng; Mingwei Sun; Jijun Chen; Yichun Zheng
Journal:  Biomed Res Int       Date:  2019-09-30       Impact factor: 3.411

View more
  2 in total

1.  A call for HoLEP: en-bloc vs. two-lobe vs. three-lobe.

Authors:  Frank Rücker; Karin Lehrich; Axel Böhme; Mario Zacharias; Sascha A Ahyai; Jens Hansen
Journal:  World J Urol       Date:  2021-01-24       Impact factor: 4.226

2.  Outcome of Patients With Elevated Prostate-Specific Antigen and Lower Urinary Tract Symptoms Receiving Holmium Laser Enucleation of the Prostate.

Authors:  Hahn-Ey Lee; ByungWon Kim; Hyun Sik Yoon; Jungyo Suh; Seung-June Oh
Journal:  Int Neurourol J       Date:  2022-09-30       Impact factor: 3.038

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.